Cover Story Featured Article Product Launch Distribution Expansion Regulatory Milestone Study Results Bora Biologics and Protect Animal Health Partner to Advance Veterinary Antibody Pipeline Strategic Collaboration Bora Biologics and Protect Animal Health have entered a long-term, multi-pr...
Quick Takeaways: Why It Matters? Bora Biologics’ first animal‑health collaboration with Protect Animal Health gives Protect a U.S./Taiwan CDMO partner (CHO‑K1 cell line, process development, scale‑up, manufacturing) to advance at least three antibody programs (two mAbs, o...
Quick Takeaways: Why It Matters? BiomEdit’s USDA conditional licensure for CPerf LLV (to be branded Optavant) creates the first genetically engineered probiotic biologic for poultry, offering a non‑antibiotic tool against necrotic enteritis-a disease costing the global broiler ...
Quick Takeaways: Why It Matters? ECO Animal Health’s acceptance of field safety data for Ecovaxxin MS by the USDA‑CVB is a key regulatory step toward US licensure of its Mycoplasma synoviae poultry vaccine, following the product’s EU commercial launch in July 2026. The large fi...
Quick Takeaways: Why It Matters? Elanco’s $120M expansion of its Elwood, Kansas site quadruples monoclonal antibody capacity and adds upstream/downstream processing, a pilot plant and QC lab, directly supporting its new biologics franchise (Befrena&nbs...
Quick Takeaways: Why It Matters? With 138 horses across eight practices showing significantly better outcomes and nearly triple the odds of returning to prior performance, the data should help veterinarians justify using equicenta CTM as a convenient, regenerative alternative to harvesting...
Quick Takeaways: Why It Matters? Medgene’s launch could be a meaningful de-risking event for cattle producers because it creates the first U.S. prescription vaccine option for a parasite with severe herd-level consequences and no approved treatment, potentially reducing losses from mortali...
Quick Takeaways: Why It Matters? Zoetis’s Portela launch should expand the feline OA market by turning a hard-to-manage, underdiagnosed condition into a more actionable treatment segment, especially because the therapy offers a three-month injectable option that is easier for owners to kee...
Quick Takeaways: Why It Matters? Zoetis’s launch of Lenivia (izenivetmab) in Canada and the EU introduces the first long-acting monoclonal antibody for canine osteoarthritis that binds a different NGF site than existing anti‑NGF therapies, offering up to three months of pain relief from a ...
Quick Takeaways: Why It Matters? Zoetis’ EC approval of Poulvac Procerta HVT-ND turns its single-dose, dual ND+Marek’s protection into a mainstream EU option, which should drive rapid adoption as producers shift from multi-vaccine schedules to a streamlined, in‑ovo or hatch-day protocol th...
